Melanoma MDx Firm DermTech Withdraws Planned $15M IPO | GenomeWeb

NEW YORK (GenomeWeb) – Melanoma test development firm DermTech is pulling its proposed initial public offering.

The La Jolla, Calif.-based firm filed a request with the US Securities and Exchange Commission on Thursday saying it seeks an "immediate withdrawal" of its Form S-1 "as it has determined not to proceed with an offering at this time." It did not provide a reason for the withdrawal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.